RJV Network News Release
Tuesday, 03-Dec-2002 10:20AM PST
BELLEVUE, Wash.--(BUSINESS WIRE)--Dec. 3, 2002--RJV Network, Inc. (OTCBB:RJVN), a Nevada corporation, announces further developments of BioKinetix Research Inc., the company it is acquiring.
In addition to its exclusive license agreement with InNexus Corporation to develop a cancer therapy using Super Antibody Technology, BioKinetix has obtained a world-wide license from BioCurex Inc. This license is for the therapeutic development of RECAF (Receptor Alpha Fetaprotein) antibodies using InNexus' Super Antibody platform technology.
Created over ten years of expensive research and development, RECAF technology is able to effectively locate molecules (markers) that are present on active cancer cells, but not on healthy cells. The combination of these two technologies gives BioKinetix the potential to create a series of therapeutic products that may treat most cancers. The therapeutics to be developed are monoclonal antibodies that mark growth factor receptor on cancer tissue. Combining RECAF antibodies with Super Antibody technology will give BioKinetix the potential to create both highly potent therapeutic antibodies, as well as vaccines to immunize against the RECAF receptor.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission.
On behalf of the Board of Directors,
Mr. Edward Velton, President
216.239.51.100 |
